Levofolic (Levoleucovorin Disodium)

Levoleucovorin is a reduced form of folic acid that bypasses the dihydrofolate reductase step, directly supplying tetrahydrofolate cofactors needed for DNA synthesis and repair. This restores normal cellular function after antifolate exposure and stabilizes the binding of fluoropyrimidines to their target enzymes.

The dose of Levofolic is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and concurrent therapies. Healthcare professionals calculate the appropriate amount and infusion rate for each individual case.

Safety data for Levofolic during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Levofolic, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Levofolic (levoleucovorin disodium) is chemically equivalent to leucovorin calcium but is supplied as a sodium salt, offering comparable efficacy in methotrexate rescue and chemotherapy support. Choice between formulations often depends on regional availability, stability preferences, and specific hospital protocols.

Levofolic must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should remain in its original packaging, must not be frozen or shaken, and should be used within the shelf‑life indicated by the manufacturer after removal from controlled storage.

Levofolic is given by intravenous infusion. The solution is diluted in an appropriate compatible fluid and administered over a period defined by the treating physician, typically ranging from a few minutes to several hours depending on the clinical scenario.

Serious risks include anaphylactic or severe hypersensitivity reactions, acute renal impairment, hypotension or shock, cardiac arrhythmias, and rare thromboembolic events. Prompt recognition and discontinuation of the product are essential if any of these events occur.

Levofolic should be avoided in patients with known hypersensitivity to levoleucovorin or any component of the formulation, and in individuals receiving high‑dose antifolate chemotherapy where rescue is not intended. Caution is also advised for patients with severe renal or hepatic impairment.